Dr. Kundan Singh Sengar has been appointed as the Chief Operating Officer (COO) at Hetero Drugs Ltd., bringing over two decades of experience in the pharmaceutical industry. His extensive background spans leadership roles at prestigious organizations like AMNEAL Life Sciences Private Limited, Pfizer, and Aurobindo Pharma Ltd., where he demonstrated expertise in sterile operations, manufacturing leadership, and operational transformation. Dr. Sengar’s experience has been instrumental in enhancing operational efficiency, managing quality processes, and ensuring compliance with global regulatory standards, particularly for complex and oncology injections.
At Hetero, Dr. Sengar will oversee all sterile operations sites, including manufacturing, engineering, audits, and quality functions. His primary responsibility will be ensuring compliance with USFDA standards while leading strategic initiatives to optimize operational processes. With his deep knowledge of sterile manufacturing operations, Dr. Sengar is expected to bring innovations that will further elevate Hetero’s quality standards and operational benchmarks, enhancing the company’s position in the global pharmaceutical market.
Before joining Hetero, Dr. Sengar served as Associate Vice President of Operations at AMNEAL Life Sciences and Pfizer, where he was responsible for leading key initiatives in sterile operations. His work at Aurobindo Pharma, where he served as Vice President of Operations, also strengthened his capabilities in driving operational excellence in pharmaceutical manufacturing. Dr. Sengar’s vast experience in managing cross-functional teams and his ability to deliver on operational objectives will be crucial in his new role.
Dr. Sengar’s leadership at Hetero Drugs Ltd. will play a pivotal role in the company’s ongoing transformation. His focus on ensuring compliance with USFDA standards and his dedication to improving operational efficiency will support Hetero’s mission to produce high-quality pharmaceutical products for patients worldwide. With his proven track record and strong industry knowledge, Dr. Sengar is well-positioned to drive Hetero’s future growth and success, making significant contributions to the company’s global expansion in the pharmaceutical sector.